Teva Pharmaceutical Industries Limited’s (TEVA) Hold Rating Reiterated at Cantor Fitzgerald

Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “hold” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research note issued to investors on Monday. They presently have a $17.00 price target on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 0.06% from the stock’s current price.

A number of other research analysts have also weighed in on TEVA. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $31.94 price target on the stock. in a research note on Monday, May 22nd. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, May 31st. ValuEngine lowered shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub raised shares of Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 13th. Finally, Mizuho raised shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and raised their price target for the company from $25.00 to $30.00 in a research note on Thursday, June 15th. Five equities research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $31.20.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded up 0.436% during midday trading on Monday, hitting $17.064. The stock had a trading volume of 14,547,553 shares. Teva Pharmaceutical Industries Limited has a 52-week low of $15.22 and a 52-week high of $51.51. The firm has a 50 day moving average price of $18.56 and a 200-day moving average price of $28.33. The stock’s market cap is $17.34 billion. Teva Pharmaceutical Industries Limited also was the recipient of some unusual options trading activity on Monday. Stock investors acquired 20,895 put options on the company. This is an increase of 103% compared to the typical daily volume of 10,273 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.25 earnings per share. Equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://ledgergazette.com/2017/09/19/teva-pharmaceutical-industries-limiteds-teva-hold-rating-reiterated-at-cantor-fitzgerald.html.

Large investors have recently bought and sold shares of the business. San Francisco Sentry Investment Group CA acquired a new position in shares of Teva Pharmaceutical Industries Limited in the second quarter worth $106,000. Bronfman E.L. Rothschild L.P. grew its stake in shares of Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after acquiring an additional 261 shares in the last quarter. Kistler Tiffany Companies LLC grew its stake in shares of Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after acquiring an additional 1,571 shares in the last quarter. FNY Managed Accounts LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited in the first quarter worth $123,000. Finally, Sterling Investment Advisors Ltd. grew its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 56.76% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply